Flavokawain B (Synonyms: Flavokavain B)

目录号: HY-N2132 纯度: 99.99%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Flavokawain B (Flavokavain B) 是一种口服活性的查耳酮。Flavokawain B 可激活 caspase-9、-3 和 -8，切割 PARP。Flavokawain B 可下调 Bcl-2，同时增加 Bax 水平。Flavokawain B 可抑制 NF-κB、PI3K/Akt 和 MAPK 信号通路。Flavokawain B 具有凋亡 (Apoptotic) 作用。Flavokawain B 可抑制 MMP-9 和促进 ROS 生成。Flavokawain B 可抑制多种肿瘤和炎症。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Flavokawain B Chemical Structure

CAS No. : 1775-97-9

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥2000	In-stock
10 mg	￥3200	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Flavokawain B:

Flavokawain B (Standard) 询价

MCE 顾客使用本产品发表的 2 篇科研文献

Flavokawain B 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Caspase 亚型特异性产品:

查看所有亚型

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

查看 PARP 亚型特异性产品:

查看所有亚型

PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

查看 Bcl-2 Family 亚型特异性产品:

查看所有亚型

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

查看 PI3K 亚型特异性产品:

查看所有亚型

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

查看 Akt 亚型特异性产品:

查看所有亚型

Akt Akt1 Akt2 Akt3

查看 p38 MAPK 亚型特异性产品:

查看所有亚型

p38 MAPK p38α p38β MAPK13 p38δ p38γ

查看 MMP 亚型特异性产品:

查看所有亚型

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

生物活性
纯度 & 产品资料
参考文献

生物活性

Flavokawain B (Flavokavain B) is an orally active chalcone. Flavokawain B results in activation of caspase-9, -3 and -8, cleavage of PARP. Flavokawain B down-regulates Bcl-2 with concomitant increase in Bax level. Flavokawain B inhibits NF-κB, PI3K/Akt and MAPK signaling pathway. Flavokawain B exhibits Apoptotic effects. Flavokawain B inhibits MMP-9 and promotes ROS generation. Flavokawain B inhibits multiple tumors and inflammation^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 20 μM Compound: 7	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
A549	IC₅₀	19.7 μM Compound: 21	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
A549	IC₅₀	8 μg/mL Compound: Flavokawain B	Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay	[PMID: 19716299]
B16-F10	IC₅₀	7.7 μM Compound: 1a	Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days	[PMID: 25597012]
Caco-2	IC₅₀	9.9 μM Compound: 2	Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
Fibroblast	IC₅₀	> 20 μM Compound: 2	Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HaCaT	IC₅₀	13.6 μM Compound: 2	Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HCT-116	IC₅₀	> 20 μM Compound: 21	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
HCT-116	IC₅₀	7.5 μM Compound: 2	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HeLa	IC₅₀	> 20 μM Compound: 21	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
Huh-7	IC₅₀	15.9 μM Compound: 2	Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MCF7	IC₅₀	15.5 μM Compound: 2	Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MDA-MB-231	IC₅₀	16.3 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MIA PaCa-2	IC₅₀	18.2 μM Compound: 21	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
NCI-H727	IC₅₀	11.3 μM Compound: 2	Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
NIH3T3	IC₅₀	3.3 μM Compound: 2b	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
PC-3	IC₅₀	9.1 μM Compound: 2	Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
RAW264.7	IC₅₀	26.5 μM Compound: FK B	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32208222]
RAW264.7	IC₅₀	4.2 μM Compound: FK B	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 32208222]
REH	IC₅₀	> 20 μM Compound: 21	Cytotoxicity against human REH cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human REH cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]
RL	IC₅₀	8.2 μM Compound: 2	Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
U-937	IC₅₀	> 20 μM Compound: 21	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	[PMID: 31673309]

体外研究
(In Vitro)

Flavokawain B (1-5 µg/mL，18-24 h) 抑制人脑内皮细胞 (HUVEC) 迁移和管形成^[1]。
Flavokawain B (1.25-20 µg/mL，18 h) 通过下调 PI3K/Akt 轴诱导多种 B 细胞淋巴瘤细胞系增殖抑制和凋亡^[3]。
Flavokawain B (5-40 µM，1 h) 具有抗炎活性，可抑制 LPS 诱导的 RAW 264.7 细胞中 NO 和 PGE2 的产生^[4]。
Flavokawain B (17.6-70.4 μM，24 h) 导致 KB 细胞凋亡，表现为细胞活力丧失、形态学改变变化、基因组 DNA 碎片化和亚 G1 期积累^[5]。
Flavokawain B (2.5-7.5 µg/mL，24 h) 诱导滑膜肉瘤细胞系凋亡^[6]。
Flavokawain B (2.5-7.5 µg/mL，24 h) 通过 G2/M 细胞周期停滞和凋亡抑制人骨肉瘤细胞 (143B 和 saos-2) 的生长^[7]。
Flavokawain B (1.25-10 μg/mL，24 h) 通过细胞内 ROS 生成和 Akt/p38 MAPK 信号下调诱导人口腔癌 HSC-3 细胞凋亡通路^[8]。
Flavokawain B (2.5-5 μg/mL，24 h) 表现出强大的凋亡作用，并诱导子宫平滑肌肉瘤细胞系 SK-LMS-1 和 ECC-1 的 G2/M 停滞^[9]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	SUDHL-4, OCI-Ly3, Raji, and Jeko-1
Concentration:	1.25, 2.5, 5, 10, 20 µg/mL
Incubation Time:	24 h, 48 h
Result:	Showed dose- and time-dependent inhibition of cell proliferation (SUDHL-4). Mildly affected cell (SUDHL-4) viability at a concentration of 1.25 μg/mL (24 h).

Apoptosis Analysis^[3]

Cell Line:	SUDHL-4, OCI-Ly3, Raji, and Jeko-1
Concentration:	2.5, 5, and 10 µg/mL
Incubation Time:	12 h, 24 h
Result:	Increased the number of cleaved PARP and caspase-3 fragments. Reduced the expression of BCL-XL (an anti-apoptotic member of the BCL-2 family). Induced the breakdown of MMP.

体内研究
(In Vivo)

Flavokawain B (1-2.5 µg/mL，24 h) 抑制斑马鱼模型中的血管生成^[1]。
Flavokawain B (50-200 mg/kg，腹腔注射) 在 LPS 诱导的小鼠中表现出抗炎活性^[4]。
Flavokawain B (0.35-0.75 mg/kg，腹腔注射，每 2 天一次，27 天) 显着抑制裸鼠体内人类 KB 细胞衍生肿瘤异种移植瘤的生长^[5]。
Flavokawain B (20-40 mg/kg，口服，7 天) 通过靶向 TLR2 抑制结肠炎小鼠中的 NF-κB 炎症信号通路激活^[10]。
Flavokawain B (25 mg/kg，口服，每天一次，持续一周) 通过调节 IKK/NF-κB 和 MAPK 信号通路，在小鼠中诱导 GSH 敏感的氧化应激^[11]。
Flavokawain B (10-20 mg/kg，例如，连续 3 天) 通过靶向髓系分化因子 2，缓解小鼠 LPS 诱导的急性肺损伤^[12]。
Flavokawain B (25 mg/kg，腹腔注射，每周两次，持续 2 周) 与 Cisplatin (HY-17394)/Gemcitabine (HY-17026) 联合使用，可显著抑制异种移植小鼠 (SNU-478 细胞) 模型中的肿瘤生长^[13]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice injected human KB cell^[5]
Dosage:	0.35, 0.75 mg/kg
Administration:	Intraperitoneal injection (i.p.), every 2 days, 27 days
Result:	Showed no loss of body weight. Showed time-dependent growth inhibition of tumor. Showed tumor cell inactivity or regression. Showed augmentation of apoptotic DNA fragmentation.

分子量

284.31

Formula

C₁₇H₁₆O₄

CAS 号

1775-97-9

性状

固体

颜色

Light yellow to yellow

中文名称

黄卡瓦胡椒素B

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 5 mg/mL (17.59 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5173 mL	17.5864 mL	35.1729 mL
5 mM	0.7035 mL	3.5173 mL	7.0346 mL
10 mM	0.3517 mL	1.7586 mL	3.5173 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.99%

选择批次：

Data Sheet (632 KB) SDS (393 KB)

COA (285 KB) RP-HPLC (260 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Rossette MC, et al. The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. Phytother Res. 2017 Oct;31(10):1607-1613. [Content Brief]

[2]. Li X, et al. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Cell Commun Signal. 2019 Mar 18;17(1):25. [Content Brief]

[3]. Zhao M, et al. The kava chalcone flavokawain B exerts inhibitory activity and synergizes with BCL-2 inhibition in malignant B-cell lymphoma. Phytomedicine. 2023 Nov;120:155074. [Content Brief]

[4]. Lin CT, et al. Anti-inflammatory activity of Flavokawain B from Alpinia pricei Hayata. J Agric Food Chem. 2009 Jul 22;57(14):6060-5. [Content Brief]

[5]. Lin E, et al. Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo. J Nutr Biochem. 2012 Apr;23(4):368-78. [Content Brief]

[6]. Sakai T, et al. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res. 2012 Jul;30(7):1045-50. [Content Brief]

[7]. Ji T, et al. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer. 2013 Jun 10;12:55. [Content Brief]

[8]. Hseu YC, et al. The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway. J Agric Food Chem. 2012 Mar 7;60(9):2385-97. [Content Brief]

[9]. Eskander RN, et al. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug;38(8):1086-94. [Content Brief]

[10]. Chen Y, et al. Flavokawain B inhibits NF-κB inflammatory signaling pathway activation in inflammatory bowel disease by targeting TLR2. Toxicol Appl Pharmacol. 2024 May;486:116922. [Content Brief]

[11]. Zhou P, et al. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J. 2010 Dec;24(12):4722-32. [Content Brief]

[12]. Luo W, et al. Flavokawain B alleviates LPS-induced acute lung injury via targeting myeloid differentiation factor 2. Acta Pharmacol Sin. 2022 Jul;43(7):1758-1768. [Content Brief]

[13]. Son JH, et al. Flavokawain B Inhibits Growth of Cholangiocarcinoma Cells by Suppressing the Akt Pathway. In Vivo. 2023 May-Jun;37(3):1077-1084. [Content Brief]

Flavokawain B 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5173 mL	17.5864 mL	35.1729 mL	87.9322 mL
	5 mM	0.7035 mL	3.5173 mL	7.0346 mL	17.5864 mL
	10 mM	0.3517 mL	1.7586 mL	3.5173 mL	8.7932 mL
	15 mM	0.2345 mL	1.1724 mL	2.3449 mL	5.8621 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Flavokawain B (Synonyms: Flavokavain B)

Customer Review

Other Forms of Flavokawain B:

Flavokawain B 相关抗体

MCE 顾客使用本产品发表的 2 篇科研文献

Flavokawain B 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Caspase 亚型特异性产品:

查看 PARP 亚型特异性产品:

查看 Bcl-2 Family 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

查看 PI3K 亚型特异性产品:

查看 Akt 亚型特异性产品:

查看 p38 MAPK 亚型特异性产品:

查看 MMP 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Flavokawain B 相关抗体:

摩尔计算器

稀释计算器

Flavokawain B 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z